A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat i starsze.
- •Pacjenci z chorobą nowotworową związaną z HER2, która nawróciła lub nie zareagowała na wcześniejsze leczenie.
- •Choroba nowotworowa, która postępowała mimo ostatniego leczenia lub pacjent nie tolerował poprzedniego leczenia.
- •Pacjenci z widocznymi zmianami chorobowymi na obrazach diagnostycznych (np. tomografii komputerowej).
- •Pacjenci w dobrym ogólnym stanie zdrowia, mogący wykonywać codzienne czynności.
- •Odpowiednia ilość komórek krwi oraz prawidłowe wyniki badań wątroby i nerek.
- •Serce pracuje prawidłowo (powyżej 50% wydolności).
- •Pacjenci potrafiący połykać tabletki.
✗ Disqualifies
- •Znaczące choroby serca.
- •Zakażenie wirusem HIV (chyba że wirus jest dobrze kontrolowany).
- •Aktywna choroba wątroby, taka jak zapalenie wątroby typu A, B lub C.
- •Problemy z wchłanianiem leków z przewodu pokarmowego (np. silne nudności, wymioty, choroby jelit).
- •Niekontrolowana cukrzyca.
- •Przeszczep narządu wewnętrznego w przeszłości.
- •Krwawienia do mózgu w ciągu ostatniego miesiąca lub poważne krwawienia w przeszłości.
- •Choroby płuc (z wyjątkiem łagodnych, które całkowicie ustąpiły).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (53)
UCSD Moores Cancer Center
La Jolla, United States
USC Norris Comprehensive Cancer Center
Los Angeles, United States
University of Colorado Cancer Center
Aurora, United States
University of Miami
Miami, United States
Comprehensive Hematology Oncology
St. Petersburg, United States
University of Chicago
Chicago, United States
Massachusetts General Hospital
Boston, United States
Dana Farber Cancer Institute
Boston, United States
University of Michigan
Ann Arbor, United States
Henry Ford Cancer Institute
Detroit, United States
START - Midwest Cancer Research Center
Grand Rapids, United States
Saint Luke's Cancer Institute
Kansas City, United States
Washington University School of Medicine
St Louis, United States
Dartmouth Hitchcock Medical
Lebanon, United States
Rutgers Cancer Institute
New Brunswick, United States
Icahn School of Medicine at Mount Sinai
New York, United States
Duke Cancer Institute
Durham, United States
University Hospital Cleveland Medical Center
Cleveland, United States
Cleveland Clinic
Cleveland, United States
OU Health Stephenson Cancer Center
Oklahoma City, United States
Providence Cancer Institute
Portland, United States
SCRI Oncology Partners
Nashville, United States
Vanderbilt Ingram Cancer Center
Nashville, United States
NEXT Oncology - Austin
Austin, United States
Mary Crowley Cancer Research
Dallas, United States
MD Anderson Cancer Center - University of Texas
Houston, United States
START Mountain Region
West Valley City, United States
NEXT Oncology - Virginia Cancer Specialists
Fairfax, United States
Fred Hutchinson Cancer Center
Seattle, United States
Centre Georges François Leclerc
Dijon, France
Institut de Cancerologie de l'Ouest
Saint-Herblain, France
Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole Institut Claudius Regaud "
Toulouse, France
The START center Dublin
Dublin, Ireland
Cork University Hospital, Wilton
Cork, Ireland
St. Vincent's University Hospital
Dublin, Ireland
Azienda Ospedaliero Universitaria Careggi - Largo Giovanni Alessandro Brambilla 3
Florence, Italy
Istituto Europeo di Oncologia (IEO)
Milan, Italy
Grande Ospedale Metropolitano Niguarda
Milan, Italy
Azienda Ospedaliera Universitaria Luigi Vanvitelli
Naples, Italy
Netherlands Cancer Institute-Antoni van Leeuwenhoek
Amsterdam, Netherlands
Seoul National University Hospital
Seoul, South Korea
Severance Hospital - Yonsei Cancer Center
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital Universitario Vall dHebron
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
START Madrid CIOCC, Hospital Universitario HM Sanchinarro
Madrid, Spain
Hospital Universitario Regional Málaga
Málaga, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Clinico Universitario de Valencia (INCLIVA)
Valencia, Spain
Royal Marsden NHS Foundation Trust, Royal Marsden Hospital (RMH)/Chelsea)
Chelsea, United Kingdom
Oxford University Hospitals NHS Foundation Trust Churchill Hospital
Oxford, United Kingdom
Royal Marsden NHS Foundation Trust, Royal Marsden Hospital (RMH)/Sutton
Sutton, United Kingdom
Trial contact
Iambic Therapeutics, Inc., Senior Medical Director
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.